Analysis of the Pharmaceutical Validation of Picc Line Installation Requests at the Nîmes University Hospital

Parenteral Nutrition Clinical Trial

— PICCLINIC  

Official title:

Analysis of the Pharmaceutical Validation of Picc Line Installation Requests at the Nîmes University Hospital

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04006730
• Other study ID #: Local/2018/VC-01
• Status: Completed
• Start date: October 1, 2018
• Est. completion date: March 14, 2019

Study information

• Verified date: June 2019
• Source: Centre Hospitalier Universitaire de Nimes
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The picc line is a central venous catheter inserted peripherally into a deep vein in the arm (cephalic, basilic or axillary) whose distal end is located at the junction of the superior vena cava / atrium.

It is installed for a minimum of 7 days (1), and can be stored for up to 6 months or more if it is functional. For treatments with an indication of more than 3 months, it is common practice to place an implantable catheter chamber. The main indications for picc line placement are: long-term antibiotic therapy, parenteral nutrition, chemotherapy or long-term venous approach when difficulties are encountered in applying a peripheral venous route to the patient.

Quickly adopted by medical teams, picc lines are not without risk, however, and three complications are mainly reported: catheter obstruction, deep vein thrombosis and infections.

In order to avoid any risk of unnecessary complications, it therefore seems appropriate to target the most appropriate device upstream of the procedure according to the provisional indication.

An inventory of pharmaceutical interventions carried out during picc line requests would make it possible to lay the foundations for considering actions to be implemented with the various services requesting picc line and proposals for improvement for the follow-up of patients with picc line to reduce the risk of complications.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 277
• Est. completion date: March 14, 2019
• Est. primary completion date: March 14, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Patient aged 18 or over, hospitalized at the University Hospital of Nîmes

• Benefiting from a pharmaceutical validation of the demand for picc line connected

Exclusion Criteria:

• The patient is opposed to participating in this study

Related Conditions & MeSH terms

• Parenteral Nutrition

Locations

Country	Name	City	State
France	Chu Nimes	Nîmes

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	estimate the prevalence of requesting pharmaceutical interventions with a criticality greater than or equal to 2 accepted.		2018